Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17874557 | 0.94 | TLR8 (0.59) | TLR8TLR7 | |
| SCHEMBL1104740 | 0.82 | TLR8 (0.74) | TLR8TLR7 | |
| SCHEMBL12619304 | 0.81 | TLR8 (0.73) | TLR8TLR7 | |
| SCHEMBL1802374 | 0.79 | TLR8 (0.73) | TLR8TLR7 | |
| SCHEMBL1237666 | 0.78 | TLR8 (0.72) | TLR8TLR7 | |
| SCHEMBL1094511 | 0.77 | TLR8 (0.71) | TLR8TLR7 | |
| SCHEMBL1237647 | 0.77 | TLR8 (0.82) | TLR8TLR7 | |
| SCHEMBL1238138 | 0.76 | TLR8 (0.69) | TLR8TLR7 | |
| SCHEMBL24860058 | 0.76 | TLR8 (0.64) | TLR8TLR7 | |
| SCHEMBL10325097 | 0.75 | TLR8 (0.63) | TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160213776-A1 | ADSORPTION OF IMMUNOPOTENTIATORS TO INSOLUBLE METAL SALTS | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2016-07-28 | — | — | US | disclosed |
| US-20160213776-A1 | ADSORPTION OF IMMUNOPOTENTIATORS TO INSOLUBLE METAL SALTS | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2016-07-28 | — | — | US | disclosed |
| US-9375471-B2 | Adjuvanted formulations of booster vaccines | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2016-06-28 | — | — | US | disclosed |
| US-9315530-B2 | Adsorption of immunopotentiators to insoluble metal salts | NOVARTIS AG (CH) | 2016-04-19 | — | — | US | disclosed |
| US-9315530-B2 | Adsorption of immunopotentiators to insoluble metal salts | NOVARTIS AG (CH) | 2016-04-19 | — | — | US | disclosed |
| EP-2719395-A1 | Adsorption of immunopotentiators to insoluble metal salts | Novartis AG (CH) | 2014-04-16 | — | — | EP | disclosed |
| EP-2480253-B1 | ADSORPTION OF IMMUNOPOTENTIATORS TO INSOLUBLE METAL SALTS | NOVARTIS AG (CH) | 2014-01-22 | — | — | EP | disclosed |
| EP-2480253-B1 | ADSORPTION OF IMMUNOPOTENTIATORS TO INSOLUBLE METAL SALTS | NOVARTIS AG (CH) | 2014-01-22 | — | — | EP | disclosed |
| US-20130274465-A1 | ADSORPTION OF IMMUNOPOTENTIATORS TO INSOLUBLE METAL SALTS | IRM LLC (BM) | 2013-10-17 | — | — | US | disclosed |
| US-20130274465-A1 | ADSORPTION OF IMMUNOPOTENTIATORS TO INSOLUBLE METAL SALTS | IRM LLC (BM) | 2013-10-17 | — | — | US | disclosed |
| US-20120177681-A1 | Formulation of immunopotentiators | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2012-07-12 | — | — | US | disclosed |
| WO-2012031140-A1 | ADSORPTION OF IMMUNOPOTENTIATORS TO INSOLUBLE METAL SALTS | NOVARTIS AG (CH) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274465-A1 | ADSORPTION OF IMMUNOPOTENTIATORS TO INSOLUBLE METAL SALTS | CD69, CD209, CD4 | TLR8 1195/4885TLR7 776/4885 |
| US-20120177681-A1 | Formulation of immunopotentiators | CD69, CD4, ICOS | TLR8 516/4885TLR7 324/4885 |
| US-20160213776-A1 | ADSORPTION OF IMMUNOPOTENTIATORS TO INSOLUBLE METAL SALTS | CD69, CD209, CD4 | TLR8 1195/4885TLR7 776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.